Background Post-partum haemorrhage (PPH) is a major cause of maternal mortality globally. Tranexamic acid, an anti-fibrinolytic agent, is a novel approach in an attempt to prevent this dreadful complication. This study aims to document the efficacy of intravenous (IV) tranexamic acid in reducing blood loss during and after caesarean section (CS). Methods In this prospective randomised placebo-controlled open-label study, 100 mothers scheduled for elective CS were randomly selected and divided into two groups (study and control) of 50 each. The study group received 1 g IV tranexamic acid and the control group received IV placebo. Following delivery, all mothers received ten units of oxytocin in 500 ml of normal saline.
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Background
Post-partum haemorrhage (PPH) is a major complication after both vaginal and caesarean delivery worldwide which contributes substantially to maternal mortality and near misses. Each year, about 1-2 % of mothers with PPH die, with an average interval of about 2-4 h from onset of PPH to death [1] . PPH is defined as the loss of more than 500 ml of blood following normal delivery or more than 1000 ml loss following caesarean section [2] . There are four causes of PPH: uterine atony, trauma to the birth passage, retained placental tissue or membranes and coagulopathies such as DIC [3] . PPH can reach disastrous proportions during caesarean section.
Management of haemorrhage after CS may range from administration of oxytocics and blood transfusion to more radical measures such as hysterectomy [4, 5] . Use of antifibrinolytic agent such as tranexamic acid (TXA), however, avoids both the hazards of blood transfusion as also the long-term side effects of hysterectomy.
The aim of this study is to assess the effect of IV tranexamic acid on blood loss during and after CS.
Materials and Methods
A randomised, placebo-controlled, open-label clinical study was conducted after Institutional Ethics Committee approval, from May 2012 to April 2013 with 100 clinically stable singleton antenatal mothers (aged 20-40 years) at term scheduled for elective caesarean section. Pregnancy complications such as pre-eclampsia, polyhydramnios, macrosomia, multiple pregnancy, preterm labour, placenta praevia and abruptio placentae were excluded from the study as also mothers with blood dyscrasias, coagulation disorders, thromboembolic disorders, severe anaemia, allergy to tranexamic acid and severe medical and surgical complications involving the heart, liver or kidney.
Sample size was calculated assuming that a difference of 100 ml of total (intra-and post-operative) blood loss would be a clinically important difference between the two groups. It was calculated that 45 subjects would be required per group in order to detect this difference with 80 % power and 5 % probability of type 1 error. Standard deviation was assumed to be 190 for control group and 150 for the test group on the basis of earlier study [6] . Adjusting for 10 % drop out rate, recruitment target was set at 50 subjects per group. Figure 1 shows The selected 100 mothers were randomised into the two groups using a computer-generated randomisation list to receive either 1 g (in 10 ml) of intravenous (IV) tranexamic acid dissolved in 20 ml of 5 % Dextrose solution (study group; n = 50) or IV placebo i.e. 30 ml of 5 % Dextrose solution (control group; n = 50), 20 min before beginning of spinal anaesthesia. During CS, after draining the amniotic fluid completely and delivery of placenta, blood was drained in a separate suction container. Dry and soaked mops and sheets were weighed by a sensitive weighing machine.
Mean blood loss from mops and sheets was calculated using the formula used by Gai et al. [7] : blood from mops and sheets = (weight of soaked material-weight of dry material)/1.05, where 1.05 is the specific gravity of blood at 37°C. To this, the blood drained in the suction container after delivery of placenta was added to get the total intraoperative blood loss.
After delivery 10 units of oxytocin in 500 ml of normal saline was infused intravenously over 20-30 min. Additional 15 units of oxytocin were given post-operatively (5U in each bottle of IV fluid for three consecutive bottles over a period of 12 h). Further administration of oxytocin was according to requirement. Two hour post-operative blood loss was calculated from the soaked pads by the same formula mentioned above.
Two hour post-operative vitals (pulse, systolic and diastolic blood pressure, respiratory rate and pallor) were compared with the pre-operative status in both groups. Preand 24 h post-operative complete blood count, coagulation profile, liver function test and renal function test were compared between the two groups.
Results
The data were expressed as mean ± SD, frequency and percentage. A preliminary test of normalcy (KolmogorovSmirnov test) was carried out for the distribution of the data. Numerical variables were compared with independent sample t test and Mann-Whitney U test, while categorical variables were dealt with Chi-square test and Fisher's exact test as appropriate. Two-tailed p value \0.05 was considered as significant. For the data analysis, standard statistical software such as Microsoft excel, SPSS version 11.5 were utilised. Table 1 shows that the two groups were equally matched with respect to demographic characteristics (viz. age, weight, height, gravida, parity), period of gestation at which caesarean section was done, indications for elective caesarean section, pre-operative vitals (pulse, systolic blood pressure, diastolic blood pressure, respiratory rate, pallor) and pre-operative haematological work-up such as complete blood count, liver function tests and renal function tests. Table 2 shows that both intra-operative and 2 h postoperative blood loss are significantly less in the study group than the control group. Table 3 shows the post-operative status of the study and the control groups. Comparison of 2 h post-operative vitals between the two groups shows that pallor (p = 0.004) and pulse rate (p = 0.000) were significantly lower in the study group. Systolic blood pressure, diastolic blood pressure and respiratory rate did not have any significant difference in the two groups post-operatively. Post-operative fall in haemoglobin per cent was significantly more in control (0.99 g%) group than study group (0.26 g%) (p = 0.000). Other parameters, viz. total count, platelet count, prothrombin time and activated plasma thromboplastin time, bilirubin and liver enzymes, urea and creatinine, did not have any significant difference in the two groups. There was no significant difference in the APGAR values at 1 min (p = 0.559) and also at 5 min (p = 0.910) between the groups. The incidences of the adverse effects such as nausea, vomiting and diarrhoea were not significantly increased in the study group as compared to the control group. There was no evidence of thrombosis in any of the mothers in the study group.
Discussion
Tranexamic acid exerts its anti-fibrinolytic effect by blocking the lysine binding locus of the plasminogen and plasmin molecules, thereby preventing the binding of plasminogen and plasmin to the fibrin substrate. Tranexamic acid also inhibits conversion of plasminogen to plasmin [8] . After delivery of baby, there is transient activation of fibrinolytic cascade for 6-10 h [7] . So the efficacy of an anti-fibrinolytic agent such as tranexamic acid is being evaluated for the prevention of PPH.
The results show that intra-operatively, mothers in the study group had mean blood loss of 499.11 ± 111.2 ml, while mothers in control group had mean blood loss of 690.85 ± 198.41 ml (p = 0.000). Two hours post-operatively, the study group had mean blood loss of 59.93 ± 12.5 ml, while the control group had mean blood loss of 110.06 ± 13.47 ml (p = 0.000). Coupling the two results, mothers in the study group had mean total blood loss of 559.68 ± 113.80 ml, while mothers in control group had mean total blood loss of 800.91 ± 200.26 ml. Thus, in the study group, there was total reduction in blood loss by about 30 % (p = 0.000). Six mothers in the control group required extra ten units of oxytocin infusion, while only two of the mothers in tranexamic acid group required the same.
Movafegh et al. [6] performed their study with intravenous administration of 10 mg/kg of tranexamic acid 20 min before skin incision at caesarean delivery. Mean blood loss was significantly less in the tranexamic acid group compared with the control group for both intra-operative bleeding (262.5 ± 39.6 vs. 404.7 ± 94.4 ml) and post-operative bleeding (67.1 ± 6.5 vs. 141.0 ± 33.9 ml; p \ 0.001), respectively. Oxytocin administration was significantly less in the tranexamic acid group compared with the control group (39 ± 5.8 vs. 43 ± 5.4 units; p = 0.001). These results were consistent with the present study.
A similar study was carried out by Ming-ying Gai et al. [7] in China by administering tranexamic acid 10 min before skin incision. The intervention led to less bleeding 2 h post-operatively, 42.75 ± 40.45 ml in the study group versus 73.98 ± 77.09 ml in the control group (p = 0.001) but did not show any decrease in post-placental delivery blood loss. This was probably due to the fact that tranexamic acid was administered only 10 min before the skin incision. Thus, the present study was designed to administer tranexamic acid 20 min before spinal anaesthesia.
Sekhavat et al. [9] conducted a prospective randomised study on 90 primipara mothers which showed that tranexamic acid significantly reduced blood loss from the end of caesarean section to 2 h post-partum; 28.02 ± 5.53 ml blood loss in the tranexamic group versus 37.12 ± 8.97 ml in the control group (p = 0.000). These results were comparable to our study although they studied only primipara, whereas our study had no inclusion criteria based on parity.
In our study, post-operatively, there was significantly more pallor in the control group than the study group (38 vs. 24) (p = 0.004).There was also significant increase in pulse, mean 84/min in study group versus 92/min in control group (p = 0.000). Other parameters such as systolic blood pressure, diastolic blood pressure and respiratory rate did not have any significant difference in the two groups. In the study by Movafegh et al. [6] and Gai et al. [7] , there was no significant increase in pulse as also the other post-operative vitals.
There was significant difference in post-operative haemoglobin levels between the two groups, mean concentration being 10.0 g% in study group versus 8.8 g% in control group (p = 0.000). The difference between the preoperative and post-operative haemoglobin values was also significantly less in the study group than the control group (p value = 0.000). Other haematological and biochemical parameters did not have any significant difference in the two groups. These results were comparable with the study by Movafegh et al. [6] and Gai et al. [7] .
Side effect profile of tranexamic acid such as nausea, vomiting and diarrhoea was similar in both groups. These results were similar to previous studies. The incidence of thrombosis during pregnancy and puerperium is 5-6 times higher than that in the general population. When the antifibrinolytic drug tranexamic acid is administered, the increased risk of thrombosis should be considered, especially in the post-partum LSCS population. In our study, however, none of the mothers developed signs of thrombosis. Svanberg et al. [10] reported 67 cases of abruptio placentae being treated by tranexamic acid without any signs of thrombosis in any. Similar results were found in other studies [6, 7, 9] . All data demonstrated that tranexamic acid can be used safely without increasing the occurrence of thrombosis, but still more studies are needed in this regard.
The safety of giving tranexamic acid (1 g) while the foetus was still in utero was a key concern. As a consequence, the neonatal outcome was meticulously evaluated by a neonatologist. In the current study, the mean APGAR scores at 1 and 5 min were 7.06 ± 1.25 and 8.66 ± 1.00 in the study group and 7.18 ± 1.35 and 8.64 ± 0.98 in the control group. Thus, there was no significant difference in the APGAR values at 1 min (p = 0.559) and also at 5 min (p = 0.910) among the two groups. None of the babies required NICU admission. Results were comparable to previous studies [6, 7, 9, 11, 12] .
To conclude, antenatal administration of intravenous tranexamic acid 20 min before spinal anaesthesia significantly reduces the amount of blood loss during and after lower segment caesarean section without any untoward adverse effects on the mother or the baby.
Compliance with Ethical Standards
Conflict of interest The authors declare that they have no conflicts of interest.
Research involving human participants and/or animals No animals were involved in this study. Only human participants were included in both case and control.
Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed Consent Written informed consent has been taken from all patients participating in the trial.
